All In Biotech

Drug Trial Radar · NCT02998879

Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis

A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated Velmanase Alfa (Recombinant Human Alpha-mannosidase) Treatment in Pediatric Patients Below 6 Years of Age With Alpha-Mannosidosis

Last checked: Nov 20, 2026Latest source record: Oct 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Dec 2016

Primary completion

Jul 2020

Study completion Jul 2020

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
Collaborators
Cromsource
First posted
Dec 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of the study are to evaluate safety and efficacy of repeated treatment with recombinant human alfa-mannosidase of patients with alfa-mannosidosis aged less than 6 years

Conditions

  • Alpha-Mannosidosis

Interventions

  • Velmanase Alfa (e.g. Lamazym)Drug

    iv infusion treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of velmanase alfa as per Adverse eventsTime frame: From baseline throughout study completion, at least of 2 years
  2. Safety and tolerability of velmanase alfa as per vital signsTime frame: From baseline throughout study completion, at least of 2 years
  3. Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per hematologyTime frame: From baseline throughout study completion, at least of 2 years
  4. Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per blood biochemistryTime frame: From baseline throughout study completion, at least of 2 years
  5. Safety and tolerability of velmanase alfa as per clinical laboratory parameters as per urinalysisTime frame: From baseline throughout study completion, at least of 2 years
  6. Detection of anti-velmanase alfa-IgG antibodies (ADA) and neutralizing/inhibitory antibodiesTime frame: From baseline throughout study completion, at least of 2 years

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Vienna, Austria

  • Site not named

    Copenhagen, Denmark

  • Site not named

    Lyon, France

  • Site not named

    Hamburg, Germany

  • Site not named

    Mainz, Germany

  • Site not named

    Trieste, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.